1-3 of 3
Lifan Tu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

JAK/Rock Inhibitor Rovadicitinib for Glucocorticoid-Refractory or -Dependent Chronic Graft-Versus-Host Disease：Updated Results of Multicenter, Phase 1b/2a Trial

Yanmin Zhao, Yi Luo, Jimin Shi, Shunqing Wang, Caixia Wang, Erlie Jiang, Chen Liang, Xiaoyu Zhu, Xuejun Zhang, Fankai Meng, Hua Jin, Yeqian Zhao, Jian Yu, Xiaoyu Lai, Lizhen Liu, Huarui Fu, Yishan Ye, Congxiao Zhang, Tao Wang, Lifan Tu, Xunqiang Wang, He Huang
Journal: Blood
Blood (2024) 144 (Supplement 1): 97.
https://doi.org/10.1182/blood-2024-204703
Published: 2024
Journal Articles

TQB3455 Plus Azacitidine in Patients with Newly Diagnosed, Mutant-IDH2 Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Phase 1 Trial

Wenbing Duan, Chunkang Chang, Zhiguo Wang, Hongbing Ma, Min Ouyang, Xingli Zhao, Lifan Tu, Guodong Wu, Xunqiang Wang, Xiao Jun Huang, Hao Jiang
Journal: Blood
Blood (2024) 144 (Supplement 1): 1504.
https://doi.org/10.1182/blood-2024-204972
Published: 2024
Journal Articles

JAK/Rock Inhibitor TQ05105 for Glucocorticoid-Refractory or -Dependent Chronic Graft-Versus-Host Disease：Preliminary Analysis Results of a Phase 1b/2 Study

Yanmin Zhao, Lifan Tu, Yishan Ye, Yi Luo, Jimin Shi, Jian Yu, Yi Yu, Fankai Meng, Tao Wang, He Huang
Journal: Blood
Blood (2022) 140 (Supplement 1): 10505–10506.
https://doi.org/10.1182/blood-2022-164659
Published: 2022